Navigation Links
Genova files patent for new prostate cancer treatment
Date:9/8/2009

NEW YORK, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), is pleased to announce that it has filed a patent for a novel peptide that disrupts the advance of prostate cancer and thus has blockbuster potential as a new anti-cancer drug.

The peptide, called Prostaganin, is a 21-amino compound which is highly reactive to prostate cancer cells, and has the ability to specifically target them. In laboratory experiments, Prostaganin has demonstrated an ability to preferentially bind to and disrupt certain negatively charged components of the membranes of prostate cancer cells.

Prostaganin thus has tremendous potential as a superior new form of treating prostate cancer. Current treatment methods such as surgery, radiation and chemotherapy are outmoded, unsatisfactory, and have severe side effects. Prostaganin offers a positive alternative. The peptide, bio-engineered from naturally occurring compounds in the human body, can target and destroy cancerous cells, whilst leaving surrounding healthy tissues intact, and causing no undesirable side effects. Further development of this novel peptide could revolutionize the way people fight cancer.

The demand for new and better treatments for prostate cancer has never been higher. Prostate cancer presently accounts for 30% of all the major cancers in men. The Prostate Cancer Foundation states that prostate cancer is the cancer with the largest expected increase in the next decade, and that annual incidence of the cancer will rise to 300,000 cases in the U.S. alone by 2015.

"Prostaginin represents a significant milestone in GENova's business agenda to acquire patents for the most innovative new cancer treatments," says Aaron Whiteman, CEO of GENova, "But most importantly, it represents a new generation of cancer treatments that could save millions of lives, and treat prostate cancer in men with no side effects or adverse effects on quality of life. Th
'/>"/>

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. GENova names Dr. John Savin as Vice President
2. GENova names Aaron Whiteman as CEO
3. Sun Pharmaceutical Files HSR Application for Taro Tender Offer
4. InfoLogix Files Preliminary Proxy Statement in Connection with Special Meeting of Its Stockholders to Approve Recapitalization Plan
5. VirtualHealth Technologies Files 8k Related to the August 17th Announcement of Private Access Payment and Document Modification
6. Profiles International Releases New Study Identifying Key Factors for Strategic Workforce Planning
7. "Med Records to Go" Stores Document and Image Files of Medical Facilities for Emergency Viewing
8. AMDL Inc. Files Notification of Late Filing for Form 10-Q
9. Texas Law Firm Files Multiple Suits Against Medtronic as Deadline Approaches
10. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
11. Vitamin Shoppe Files Registration Statement for Initial Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... (May 18, 2013) The use of a ... colonoscopy, according to new research presented today at ... begins days in advance of the procedure, includes ... to be taken at strict intervals. The better ... to see cancer and precancerous polyps in the ...
(Date:5/18/2013)... ground-breaking advance in colonoscopy technology signals the future ... at Digestive Disease Week (DDW). Additional research focuses ... and exploring safer methods for removing polyps. ... called a colonoscope to examine the colon. This ... to look for precancerous polyps called adenomas in ...
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & Forecast (2010 ... restraints, and opportunities in North America, Europe, Asia, & ... 89 market data tables , ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers ... healthcare IT market is expected to grow from $99.6 ...
(Date:5/18/2013)... KY (PRWEB) May 18, 2013 During ... hearing loss should consider the legal protections they have, ... when problems arise with their child’s treatment or hearing ... , Since 1927, the American Speech-Language-Hearing Association has used ... disorders and to promote treatment, such as cochlear implants, ...
(Date:5/18/2013)... Adolescents, especially young males, who experiment ... “K2” are landing in emergency rooms across America. ... epidemic with a new treatment program for those ... research from the National Institute on Drug Abuse, synthetic ... American teenagers. In 2012, 11 percent of high school ...
Breaking Medicine News(10 mins):Health News:New smartphone application improves colonoscopy preparation 2Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2
... The supervisory board of Celesio AG has today approved ... wholesaler Panpharma. This step into one of the most ... Celesio,s growth strategy. Celesio doesn,t plan to setup a ... about two years thoroughly analysing the Brazilian pharmaceutical market, ...
... mental stress not seen in those with high blood pressure, ... and other forms of mental stress cause dilation of the ... brain in healthy people, but this doesn,t occur in those ... researchers who used ultrasound imaging to monitor the carotid arteries ...
... , SACRAMENTO, Calif., July 10 After several months ... the chief executive officer of a leading statewide mental ... shop Psycho Donuts, will meet face to face to ... questionable business practices. , , Owners Kipp Berdiansky ...
... Aegis of Granada Hills has been named "Best Assisted Living ... their annual Readers Choice Awards. This is the second year in ... award. In voting, Aegis was a write-in candidate and received ... metro area to gain top status. , , ...
... 10 A sometimes fatal "superbug" is popping up in ... people live. It,s called methicillin-resistant Staphylococcus aureus, (MRSA "mer,-sa"). Health ... to slow its spread. , , "Physicians, health ... threat through the appropriate use of antibiotics, proper wound care ...
... more than half of patients reported improvement , FRIDAY, July ... asthma and other respiratory conditions shows promise in restoring a ... ability. , "More work needs to be done but, for ... an option worth trying," said Dr. Ronald Kuppersmith, clinical assistant ...
Cached Medicine News:Health News:Celesio Acquires Majority Stake in Number One Brazilian Pharmaceutical Wholesaler Panpharma 2Health News:Blood Rush to the Brain When Angry Is a Good Sign 2Health News:There Is No Way to Sugar Coat These Donuts 2Health News:Blue Cross and Blue Shield of Illinois Urges Constant Vigilance Against Growing Threat of Killer 'Superbug' 2Health News:Blue Cross and Blue Shield of Illinois Urges Constant Vigilance Against Growing Threat of Killer 'Superbug' 3Health News:Drug Might Restore Sense of Smell 2Health News:Drug Might Restore Sense of Smell 3
(Date:5/17/2013)... , May 17, 2013 Fuse Science, Inc. (OTCQB: ... company that is developing new, patent-pending technologies poised to redefine ... that it will hold a business update teleconference and webcast ... nd , 2013 at 4:30 PM ET. ... will host the call and will be joined by ...
(Date:5/17/2013)... May 17, 2013  Atossa Genetics, Inc. (NASDAQ: ... Kyle Guse , Chief Financial Officer & General ... Conference on Thursday, May 30, 2013, in New ... The Company,s presentation is scheduled to begin at ... webcast. To access the webcast, go to www.atossagenetics.com . ...
(Date:5/17/2013)... 2013 Sinovac Biotech Ltd. (Nasdaq: SVA ... , today announced that it will release its unaudited ... before market on Tuesday, May 28, 2013.  The Company will ... 8:00 a.m. EDT (May 28, 2013 at 8:00 p.m. China ... an update on recent corporate developments. To access ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: